Miami-based TissueTech Inc. has announced that it has been awarded four patents by the U.S. Patent Trademark Office. As the company wrote in its September 15, 2017 news release, “Two of the patents cover methods of promoting bone formation and the others cover methods for lyophilizing and sterilizing placental tissue.”
4 Key Ortho Patents Issued for Amniotic Allograft
2 min read Premium comments
Secondary
“TissueTech continues to maintain its status as the leader in the scientific understanding and innovative application of placental tissue in regenerative medicine,” said Amy Tseng, company CEO.
“In addition to being the recipient of four new patents, the company recently surpassed the milestone of 300,000 human implants performed by clinicians and our research is backed by more than 30 years of continuous funding through the National Institute of Health [NIH].”
“The recognition of this technology and its use in medicine underscores our success in finding new and important arenas where regenerative therapy offers the potential to address underserved and unmet clinical needs and improve patients’ lives.”
As the company wrote in its news release, “The four patents issued to TissueTech apply to: The use of placental tissue in different forms to address the typical effects of bone diseases including arthritis, osteoporosis, bone tumors, Paget’s Disease, and alveolar bone degradation; A method of promoting or inducing osteogenesis in an individual in need thereof, comprising contacting a bone or joint in the individual with a therapeutically-effective amount of placental tissue; The preservation and sterilization of placental tissue necessary to make it available to physicians for transplantation to patients in clinical need; A method of preparing a placental tissue powder product by lyophilizing placental tissue and grinding the lyophilized tissue to generate a product that can be delivered less invasively.”
”TissueTech was the first company to introduce cryopreserved umbilical cord and amniotic membrane tissues for clinical transplantation,” said Scheffer Tseng, M.D., Ph.D., company chief technology officer. “As a pioneer in this space and with the continued support of our NIH grant and the private capital that we have raised, we will continue to lead in the development of innovative technologies and delivery techniques to better serve patients across all sectors of healthcare with regenerative therapy options.”
Amy Tseng told OTW, “As the first company to commercialize the clinical use of placental tissue in ophthalmics, we have established ourselves as the market leader and the only company allowed to make wound healing claims in that sector. With our expansion into the orthopedic sector, these patents protect our best in class technology to ensure that we can offer its unique benefits to patients who require both surgical and non-surgical treatment of soft tissue and joint disease and injury.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.